Morgan Stanley Knock-Out MRK/ DE000MB5L8T2 /
19/06/2024 13:42:39 | Chg.-0.26 | Bid19/06/2024 | Ask19/06/2024 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
6.57EUR | -3.81% | 6.57 Bid Size: 15,000 |
6.58 Ask Size: 15,000 |
MERCK KGAA O.N. | 101.0349 - | 31/12/2078 | Call |
GlobeNewswire
18/06
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire
03/06
Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, ...
GlobeNewswire
29/05
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio fo...
GlobeNewswire
07/05
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
06/05
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
04/03
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
21/12/2023
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
14/12/2023
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
17/10/2023
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA